Fundraising Fox
/Companies
Sign in

HYKU Biosciences

Burlington, US · Founded 2021 · Delaware corporation · 9 employees on LinkedIn · 4 known investors

Find your way into HYKU Biosciences

Sign up to see every warm intro you have to HYKU Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the HYKU Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins. The company operates in drug discovery, using its proprietary Hyku platform to address challenges such as selectivity, druggability, and resistance in disease targets.

BiotechDeep TechMedical Devices

Founders & leadership

HYKU Biosciences was founded in 2021 by KLEEM CHAUDHARY and Ku-Lung (Ken) Hsu, PhD.

KCKLEEM CHAUDHARY
KLEEM CHAUDHARYCo-founder · President & Chief Executive OfficerExecutive and director at Hyku Biosciences, which develops small molecule therapeutics designed to target disease-driving proteins through covalent binding to non-cysteine amino acids. Chaudhary has held leadership roles across multiple biotech and pharmaceutical organizations.
K(Ku-Lung (Ken) Hsu, PhD
Ku-Lung (Ken) Hsu, PhDEndowed Associate Professor of Chemistry
KCKleem Chaudhary, PhD
Kleem Chaudhary, PhDPresident & CEO

Board

JG
JOHN GUSTOFSONBoard director
LBLAURA BRASS
LAURA BRASSBoard directorManaging Director at the Novartis Venture Fund
LTLAURA TADVALKAR
LAURA TADVALKARBoard Director2021–2026Managing Director, Venture at RA Capital
MVMATTHIAS VAN WOENSEL
MATTHIAS VAN WOENSELBoard directorPartner at Droia Ventures
JNJANWILLEM NAESENS
JANWILLEM NAESENSBoard directorManaging Partner at Droia Ventures

Investors · 4

Eisai Innovation, Inc.✓ confirmed by HYKU BiosciencesCambridge · $5M

How we know: the company's own site · Not right? Tell us

Novartis Venture Fund✓ confirmed by HYKU BiosciencesBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

RA Capital✓ confirmed by HYKU BiosciencesBoston

How we know: the company's own site · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$15.2M disclosed across 2 rounds · 2025–2026

▶$8.6MraisedAug 2026 · 4 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • KLEEM CHAUDHARYExecutive Officer, Director
  • MATTHIAS VAN WOENSELDirector
  • JOHN GUSTOFSONDirector
  • JANWILLEM NAESENSDirector
Offering amount
$8.6M
Amount sold
$8.6M
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.6MraisedJan 2026 · 8 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • JOHN GUSTOFSONDirector
  • LAURA BRASSDirector
  • LAURA TADVALKARDirector
  • KLEEM CHAUDHARYExecutive Officer, Director, Promoter
  • MATTHIAS VAN WOENSELDirector
Offering amount
$21M
Amount sold
$6.6M
First sale
Dec 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Harvard BioscienceHarvard Bioscience manufactures and supplies life science research tools and laboratory equipment for academic institutions and pharmaceutical companies. The company serves the research and development market with advanced instrumentation and solutions.
Helicore BiopharmaHelicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
Harmony BiosciencesHarmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.

Companies working in the same space as HYKU Biosciences.

Frequently asked questions

What does HYKU Biosciences do?
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins. The company operates in drug discovery, using its proprietary Hyku platform to address challenges such as selectivity, druggability, and resistance in disease targets.
Who founded HYKU Biosciences?
HYKU Biosciences was founded by KLEEM CHAUDHARY, Ku-Lung (Ken) Hsu, PhD in 2021.
Who are HYKU Biosciences's investors?
HYKU Biosciences's investors include Droia Ventures, Eisai Innovation, Inc., Novartis Venture Fund, RA Capital.
How much funding has HYKU Biosciences raised?
HYKU Biosciences has disclosed $15.2M raised across 2 rounds.
Where is HYKU Biosciences headquartered?
HYKU Biosciences is headquartered in Burlington, US.